Contrasting Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) & InspireMD (NYSE:NSPR)

InspireMD (NYSE:NSPR) and Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares InspireMD and Fresenius SE & Co. KGaA’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$6.48 million	9.08	-$19.92 million	($0.76)	-3.11
Fresenius SE & Co. KGaA	$24.01 billion	0.76	-$639.61 million	N/A	N/A

InspireMD has higher earnings, but lower revenue than Fresenius SE & Co. KGaA.

Profitability

This table compares InspireMD and Fresenius SE & Co. KGaA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InspireMD	-350.35%	-55.12%	-46.95%
Fresenius SE & Co. KGaA	N/A	N/A	N/A

Institutional & Insider Ownership

44.8% of InspireMD shares are held by institutional investors. 29.7% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for InspireMD and Fresenius SE & Co. KGaA, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0	0	1	0	3.00
Fresenius SE & Co. KGaA	0	1	2	0	2.67

InspireMD currently has a consensus price target of $4.85, suggesting a potential upside of 105.51%. Given InspireMD’s stronger consensus rating and higher possible upside, research analysts clearly believe InspireMD is more favorable than Fresenius SE & Co. KGaA.

Risk & Volatility

InspireMD has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Fresenius SE & Co. KGaA has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Summary

Fresenius SE & Co. KGaA beats InspireMD on 7 of the 13 factors compared between the two stocks.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.